Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

• ClinicalTrials.gov Identifier: NCT03945318
• Recruitment Status: Active, not recruiting
• First Posted: May 10, 2019
• Last Update Posted: April 19, 2024
• Sponsor: Chinook Therapeutics, Inc.
• Information provided by (Responsible Party): Chinook Therapeutics, Inc.

Study Description

Brief Summary:

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).

Condition or disease	Intervention/treatment	Phase
IgA Nephropathy	Drug: BION-1301 Single Dose; Drug: Placebo Single Dose; Drug: BION-1301 Multiple Doses; Drug: Placebo Multiple Doses	Phase 1; Phase 2

Detailed Description:

This is a Phase 1/2 study of BION-1301, a first-in-class humanized IgG4 anti-a proliferation-inducing ligand (APRIL) monoclonal antibody.

The study will be conducted in three parts. Part 1: double-blind, randomized, placebo-controlled, single ascending dose (SAD) in healthy volunteers (HVs). Part 2: double-blind, randomized, placebo-controlled multiple ascending dose (MAD) in HVs. Part 3: Open-label, multiple dose (MD) in participants with IgAN. Part 4: Retreatment period

Parts 1 and 2 have been completed. Part 3 enrollment is complete. Part 4 enrollment is open for eligible participants from Part 3.

The study will enroll up to 40 participants with IgAN.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 103 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Part 1 (SAD-HV) is a randomized, placebo-controlled single ascending dose design in HVs. Part 2 (MAD-HV): is a randomized, placebo-controlled multiple ascending dose design in HVs. Part 3 (MD-IgAN) is an open-label multiple dose design in participants with IgAN. Part 4 (IgAN) is open-label retreatment for Part 3 participants.
• Masking: Triple (Participant, Care Provider, Investigator)
• Masking Description: Parts 1 and 2 will be performed in a double-blind manner, for clinical research personnel interacting with study participants. An unblinded pharmacist will prepare the doses of investigational study drugs.
• Primary Purpose: Treatment
• Official Title: A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
• Actual Study Start Date: April 8, 2019
• Estimated Primary Completion Date: October 2025
• Estimated Study Completion Date: October 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Part 1: BION-1301; Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.	Drug: BION-1301 Single Dose; A solution for IV infusion administered as a single dose.
Placebo Comparator: Part 1: Placebo; Participants will receive a single dose of placebo administered by IV infusion.	Drug: Placebo Single Dose; A solution by IV infusion administered as a single dose.
Experimental: Part 2: BION-1301; Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.	Drug: BION-1301 Multiple Doses; A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
Placebo Comparator: Part 2: Placebo; Participants will receive placebo by IV infusion.	Drug: Placebo Multiple Doses; A solution by IV infusion administered as multiple doses.
Experimental: Part 3: BION-1301; Two cohorts of participants will receive multiple doses of BION-1301 by IV infusion (Cohort 1) or SC injection (Cohort 2) at 600mg/biweekly.	Drug: BION-1301 Multiple Doses; A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
Experimental: Part 4 Retreatment: BION-1301; Eligible participants from Part 3 may enroll in Part 4 due to disease progression or by choice for optional retreatment and receive SC injection at 600mg/biweekly.	Drug: BION-1301 Single Dose; SC injection administration as a single dose using vials or pre-filled syringes (PFS) (Part 4 only).

Outcome Measures

Primary Outcome Measures :

1. Incidence of Treatment Emergent Adverse Events (TEAEs) as assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: Participants followed from date of enrollment until the end of study, assessed up to 76 weeks. ]
2. Severity of TEAEs as assessed according to NCI-CTCAE [ Time Frame: Participants followed from date of enrollment until the end of study, assessed up to 76 weeks. ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria for Healthy Volunteers:

1. Healthy male or female volunteers, 18 to 55 years old
2. Females must be of non-childbearing potential
3. Males must agree to follow the protocol-specified contraception guidance
4. Body mass index (BMI) between 18 and 35 kg/m^2, with a weight of at least 50 kg
5. Non-smoker, defined as an individual who has not smoked previously and/or who has discontinued smoking or the use of nicotine/nicotine-containing products at least 3 months before Screening
6. Able to provide signed informed consent

Exclusion Criteria for Healthy Volunteers:

1. Regular consumption of alcohol within 6 months prior to Screening, or use of soft drugs (such as marijuana) within 3 months prior to Screening, or hard drugs (such as cocaine and phencyclidine) within 1 year prior to Screening and/or positive blood or urine test results for drugs of abuse or alcohol at Screening or Admission
2. Donated blood in the 3 months prior to the first dose of study drug, plasma in the 7 days prior to the first dose of study drug, or platelets in the 6 weeks prior to the first dose of study drug
3. History or evidence of a clinically significant disorder, condition, or disease that could pose a risk to subject safety or interfere with the study, or would make the subject unsuitable for participation, eg, respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, or psychiatric disease
4. Female who is breastfeeding or who has a positive serum pregnancy test at Screening or a positive urine pregnancy test on Day -1

Inclusion Criteria for Adults with IgAN:

1. Male or female ≥18 years old at Screening
2. Women of child-bearing potential (WOCBP; per CTFG 2014) must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug)
3. Males must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug)
4. BMI between 18 and 40 kg/m^2, inclusive, at Screening with a weight of at least 50 kg
5. Diagnosis of IgAN verified by biopsy taken within the past 10 years
6. Urine protein ≥ 0.5 g/24h; OR UPCR ≥ 0.5 g/g (or ≥ 50 mg/mmol)
7. eGFR (per Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) or measured GFR ≥ 30 mL/min per 1.73 m^2
8. Stable on an optimized dose of angiotensin converting enzyme (ACE) inhibitors and/or angiotensin-receptor blockers (ARBs) for at least 3 months prior to Screening or intolerant to ACE/ARB

Exclusion Criteria for Adults with IgAN:

1. Known or suspected allergy or hypersensitivity to any component of BION-1301, or history of severe hypersensitivity reaction to any monoclonal antibody
2. Donated blood in the 3 months prior to the first dose of study drug; plasma in the 7 days prior to the first dose of study drug; or platelets in the 6 weeks prior to the first dose of study drug
3. Participated in any other study in which receipt of an investigational new drug, or investigational device occurred within 28 days, or 5 half-lives (whichever is longer) of first dose of study drug in the present study
4. Secondary forms of IgAN as defined by the treating physician (eg, Henoch-Schönlein purpura patients and those with associated alcoholic cirrhosis)
5. Received systemic corticosteroid therapy (> 10 mg/day of prednisone or equivalent) or any other form of immunosuppressive therapy within 3 months prior to the first dose of study drug

PART 4 Eligibility Criteria for Re-treatment Due to Evidence of Disease Progression (Option 1) Inclusion Criteria for Re-treatment Due to Evidence of Disease Progression

1. Completed Part 3 of the study through Week 124 and entered the 52-week follow-up period.
2. UPCR ≥ 0.5 g/g AND ≥ 30% increase from EOT (Week 124). Both proteinuria criteria must be met by a 24-hour urine assessment during the 52-week follow-up period. In addition to the scheduled assessments, investigators may order periodic FMV assessments (for example monthly) to follow a patient more closely. Based on an off-schedule FMV result, or other laboratory or clinical evidence, investigators may order an off-schedule 24-urine collection to confirm disease progression.

Exclusion Criteria for Re-treatment Due to Evidence of Disease Progression

1. Based on the Investigator's judgment, the patient would not benefit from resuming treatment with BION-1301 or there is a safety concern for the individual patient which outweighs the expected benefit from resuming treatment.

Eligibility Criteria for Optional Re-treatment (Option 2) Inclusion Criteria for Optional Re-treatment 1. Completed Part 3 of the study through Week 124 and completed of the 52-week follow-up period.

Exclusion Criteria for Optional Re-treatment

1. Based on the Investigator's judgment, the patient would not benefit from resuming treatment with BION-1301 or there is a safety concern for the individual patient which outweighs the expected benefit from resuming treatment.

Contacts and Locations

Locations

United States, California

Amicis Research Center

Northridge, California, United States, 91324

United States, Colorado

Colorado Kidney Care, P.C.

Denver, Colorado, United States, 80230

United States, Florida

Nephrology Associates of Central Florida

Orlando, Florida, United States, 32806

Elixia Tampa, LLC

Tampa, Florida, United States, 33618

United States, New York

New York Nephrology

Clifton Park, New York, United States, 12065

United States, Oklahoma

Chris Sholer, P.C.

Oklahoma City, Oklahoma, United States, 73116

United States, Texas

Liberty Research Center

Arlington, Texas, United States, 76012

Liberty Research Center

Dallas, Texas, United States, 75230

Prolato Clinical Research Center

Houston, Texas, United States, 77054

Korea, Republic of

Soon Chun Hyang University Hospital Cheonan

Cheonan, Chungcheongnamdo, Korea, Republic of, 31151

Hallym University Sacred Heart Hospital

Anyang-si, Gyeonggi-do, Korea, Republic of, 14068

National Health Insurance Service Ilsan Hospital

Goyang-Si, Gyeonggi-Do, Korea, Republic of, 10444

Hanyang University Guri Hostpital

Guri-si, Gyeonggi-do, Korea, Republic of, 11923

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620

United Kingdom

Liverpool University Hospital NHS Foundation Trust

Liverpool, England, United Kingdom, L7 8XP

PAREXEL Early Phase Clinical Unit

London, United Kingdom, HA1 3UJ

Sponsors and Collaborators

Chinook Therapeutics, Inc.

Investigators

• Study Director: Novartis Pharmaceuticals; Novartis Pharmaceuticals

More Information

• Responsible Party: Chinook Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT03945318
• Obsolete Identifiers: NCT04684745
• Other Study ID Numbers: ADU-CL-19; 2018-003360-31 ( EudraCT Number )
• First Posted: May 10, 2019
• Last Update Posted: April 19, 2024
• Last Verified: April 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:

Kidney Diseases; Glomerulonephritis, IGA; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Glomerulonephritis; Nephritis; Autoimmune Diseases; Immune System Diseases